Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with SASP (high certainty).
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).
Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).
Once‐daily dosing showed no clear difference in failure to maintain clinical or endoscopic remission compared with conventional dosing (high certainty).
Once‐daily dosing showed no clear difference in failure to adhere to study medication regimen compared with conventional dosing (moderate certainty).
Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
Once‐daily dosing showed no clear difference in exclusion/withdrawal after entry compared with conventional dosing (high certainty).
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).